When used as part of CagriSema, the dosing schedule looked like this in trials: Weeks 04: 0.25 mg cagrilintide + 0.25 mg semaglutide Weeks 48: 0.5 mg + 0.5 mg Weeks 812: 1 mg + 1 mg Weeks 1216: 1.7 mg + 1.7 mg Week 16 onward: 2.4 mg + 2.4 mg (full maintenance dose) Until the medication is approved and prescribing information is finalized, any dosing decisions would only happen through participation in a clinical trial or, eventually, under the guidance of a healthcare provider
[DOI] [PMC free article] [PubMed] [Google Scholar] 46.Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, et al
Petersburg Institute of Bioregulation and Gerontology in the 1970s
Don't leave it sitting out on the bench
It doesnt just temporarily reduce inflammation
Subcutaneous formalin and intraplantar carrageenan increase nitric oxide release as measured by in vivo voltammetry in the spinal cord